204 related articles for article (PubMed ID: 16428472)
1. Expression of EphA2 and Ephrin A-1 in carcinoma of the urinary bladder.
Abraham S; Knapp DW; Cheng L; Snyder PW; Mittal SK; Bangari DS; Kinch M; Wu L; Dhariwal J; Mohammed SI
Clin Cancer Res; 2006 Jan; 12(2):353-60. PubMed ID: 16428472
[TBL] [Abstract][Full Text] [Related]
2. The clinical significance of EphA2 and Ephrin A-1 in epithelial ovarian carcinomas.
Han L; Dong Z; Qiao Y; Kristensen GB; Holm R; Nesland JM; Suo Z
Gynecol Oncol; 2005 Nov; 99(2):278-86. PubMed ID: 16061279
[TBL] [Abstract][Full Text] [Related]
3. Expression of EphA2 and E-cadherin in colorectal cancer: correlation with cancer metastasis.
Saito T; Masuda N; Miyazaki T; Kanoh K; Suzuki H; Shimura T; Asao T; Kuwano H
Oncol Rep; 2004 Mar; 11(3):605-11. PubMed ID: 14767510
[TBL] [Abstract][Full Text] [Related]
4. [Expression and clinical significance of Ephrin-A1 in primary hepatocellular carcinoma].
Zhang G; Zhang SJ; Zhao YF; Wu Y; Li Z; Wang JX
Zhonghua Wai Ke Za Zhi; 2007 Apr; 45(7):499-502. PubMed ID: 17686315
[TBL] [Abstract][Full Text] [Related]
5. EphA2 receptor tyrosine kinase regulates endothelial cell migration and vascular assembly through phosphoinositide 3-kinase-mediated Rac1 GTPase activation.
Brantley-Sieders DM; Caughron J; Hicks D; Pozzi A; Ruiz JC; Chen J
J Cell Sci; 2004 Apr; 117(Pt 10):2037-49. PubMed ID: 15054110
[TBL] [Abstract][Full Text] [Related]
6. Change of E-cadherin by hepatocyte growth factor and effects on the prognosis of hypopharyngeal carcinoma.
Kim CH; Kim J; Kahng H; Choi EC
Ann Surg Oncol; 2007 May; 14(5):1565-74. PubMed ID: 17294073
[TBL] [Abstract][Full Text] [Related]
7. EPHA2/EFNA1 expression in human gastric cancer.
Nakamura R; Kataoka H; Sato N; Kanamori M; Ihara M; Igarashi H; Ravshanov S; Wang YJ; Li ZY; Shimamura T; Kobayashi T; Konno H; Shinmura K; Tanaka M; Sugimura H
Cancer Sci; 2005 Jan; 96(1):42-7. PubMed ID: 15649254
[TBL] [Abstract][Full Text] [Related]
8. Relationship between E-cadherin and fibroblast growth factor receptor 2b expression in bladder carcinomas.
De Medina SG; Popov Z; Chopin DK; Southgate J; Tucker GC; Delouvée A; Thiery JP; Radvanyi F
Oncogene; 1999 Oct; 18(41):5722-6. PubMed ID: 10523852
[TBL] [Abstract][Full Text] [Related]
9. Prognostic value of EphA2 and EphrinA-1 in squamous cell cervical carcinoma.
Wu D; Suo Z; Kristensen GB; Li S; Troen G; Holm R; Nesland JM
Gynecol Oncol; 2004 Aug; 94(2):312-9. PubMed ID: 15297167
[TBL] [Abstract][Full Text] [Related]
10. [Expression of EphA2 and EphrinA1 in human renal cell carcinoma and its relationship with angiogenesis].
Xu JS; Zhang JX; Geng TH; Wang YF; Wang XL; Zuo LF
Zhonghua Zhong Liu Za Zhi; 2009 Jun; 31(6):438-41. PubMed ID: 19950554
[TBL] [Abstract][Full Text] [Related]
11. Predictive value of EphA2 and EphrinA-1 expression in oesophageal squamous cell carcinoma.
Xu F; Zhong W; Li J; Shanshen Z; Cui J; Nesland JM; Suo Z
Anticancer Res; 2005; 25(4):2943-50. PubMed ID: 16080548
[TBL] [Abstract][Full Text] [Related]
12. A conditional feedback loop regulates Ras activity through EphA2.
Macrae M; Neve RM; Rodriguez-Viciana P; Haqq C; Yeh J; Chen C; Gray JW; McCormick F
Cancer Cell; 2005 Aug; 8(2):111-8. PubMed ID: 16098464
[TBL] [Abstract][Full Text] [Related]
13. EphA2 as a novel molecular marker and target in glioblastoma multiforme.
Wykosky J; Gibo DM; Stanton C; Debinski W
Mol Cancer Res; 2005 Oct; 3(10):541-51. PubMed ID: 16254188
[TBL] [Abstract][Full Text] [Related]
14. Mutations within the kinase domain and truncations of the epidermal growth factor receptor are rare events in bladder cancer: implications for therapy.
Blehm KN; Spiess PE; Bondaruk JE; Dujka ME; Villares GJ; Zhao YJ; Bogler O; Aldape KD; Grossman HB; Adam L; McConkey DJ; Czerniak BA; Dinney CP; Bar-Eli M
Clin Cancer Res; 2006 Aug; 12(15):4671-7. PubMed ID: 16899617
[TBL] [Abstract][Full Text] [Related]
15. Transient receptor potential vanilloid type 2 (TRPV2) expression in normal urothelium and in urothelial carcinoma of human bladder: correlation with the pathologic stage.
Caprodossi S; Lucciarini R; Amantini C; Nabissi M; Canesin G; Ballarini P; Di Spilimbergo A; Cardarelli MA; Servi L; Mammana G; Santoni G
Eur Urol; 2008 Sep; 54(3):612-20. PubMed ID: 17977643
[TBL] [Abstract][Full Text] [Related]
16. Etodolac, a selective cyclooxygenase-2 inhibitor, induces upregulation of E-cadherin and has antitumor effect on human bladder cancer cells in vitro and in vivo.
Okamoto A; Shirakawa T; Bito T; Shigemura K; Hamada K; Gotoh A; Fujisawa M; Kawabata M
Urology; 2008 Jan; 71(1):156-60. PubMed ID: 18242386
[TBL] [Abstract][Full Text] [Related]
17. Livin may serve as a marker for prognosis of bladder cancer relapse and a target of bladder cancer treatment.
Liu HB; Kong CZ; Zeng Y; Liu XK; Bi JB; Jiang YJ; Han S
Urol Oncol; 2009; 27(3):277-83. PubMed ID: 18555709
[TBL] [Abstract][Full Text] [Related]
18. A cox-2 promoter-based replication-selective adenoviral vector to target the cox-2-expressing human bladder cancer cells.
Shirakawa T; Hamada K; Zhang Z; Okada H; Tagawa M; Kamidono S; Kawabata M; Gotoh A
Clin Cancer Res; 2004 Jul; 10(13):4342-8. PubMed ID: 15240520
[TBL] [Abstract][Full Text] [Related]
19. Cell adhesion and EGFR activation regulate EphA2 expression in cancer.
Larsen AB; Stockhausen MT; Poulsen HS
Cell Signal; 2010 Apr; 22(4):636-44. PubMed ID: 19948216
[TBL] [Abstract][Full Text] [Related]
20. Treatment with low-dose interferon-alpha restores the balance between matrix metalloproteinase-9 and E-cadherin expression in human transitional cell carcinoma of the bladder.
Slaton JW; Karashima T; Perrotte P; Inoue K; Kim SJ; Izawa J; Kedar D; McConkey DJ; Millikan R; Sweeney P; Yoshikawa C; Shuin T; Dinney CP
Clin Cancer Res; 2001 Sep; 7(9):2840-53. PubMed ID: 11555602
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
